Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Cue Biopharma(US:CUE) Globenewswire·2026-03-16 20:05Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments tot ...